Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications

Review of Diabetic Studies

Volumn 9, Issue 1, 2012, Pages 6-22

  Murea, Mariana ^a   Ma, Lijun ^a   Freedman, Barry I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Environment; Gene; GWAS; Heritability; Link age analysis; Polymorphism; Type 2 diabetes; Vascular complications

Indexed keywords

ALPHA TOCOPHEROL; ARSENIC; ATRAZINE; BENZENE DERIVATIVE; BETA CAROTENE; CALCINEURIN INHIBITOR; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; DIOXIN; ERYTHROPOIETIN; GLUCOSE; HEAVY METAL; HEPTACHLOR EPOXIDE; HERBICIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NEUROLEPTIC AGENT; NITROGEN DIOXIDE; NITROSO DERIVATIVE; ORAL CONTRACEPTIVE AGENT; ORGANOCHLORINE PESTICIDE; PESTICIDE; POLYCHLORINATED BIPHENYL DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; RADIXIN; TALC; TETRACHLOROETHYLENE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

AIR POLLUTANT; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIDEMIC; FRAMESHIFT MUTATION; FTO GENE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC MARKER; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GIPR GENE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEREDITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; IPF1 GENE; KCJN11 GENE; KCNJ11 GENE; LIFESTYLE MODIFICATION; MISSENSE MUTATION; MTNR1B GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PARTICULATE MATTER; PATHOGENESIS; PPARG GENE; PREX1 GENE; REVIEW; SGK1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TCF7L2 GENE; WFS1 GENE;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENVIRONMENTAL EXPOSURE; GENE-ENVIRONMENT INTERACTION; HUMANS;

EID: 84864388040     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2012.9.6     Document Type: Review

References (142)

1. Morgan CL, Currie CJ, Peters JR. Relationship between diabetes and mortality: a population study using re-cord linkage. Diabetes Care 2000. 23:1103-1107.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, La-akso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998. 339:229-234.
3. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003. 14:3270-3277.
4. Seshasai SR, Kaptoge S, Thompson A, Di AE, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011. 364:829-841.
5. Bonnefond A, Froguel P, Vaxillaire M. The emerging genetics of type 2 diabetes. Trends Mol Med 2010. 16:407-416.
6. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010. 33(Suppl 1):S62-S69.
7. Meigs JB, Cupples LA, Wilson PW. Parental transmis-sion of type 2 diabetes: the Framingham Offspring Study. Diabetes 2000. 49:2201-2207.
8. Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, Reunanen A, Eriksson J, Stengard J, Kesaniemi YA. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 1992. 35:1060-1067.
9. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, et al. The common PPARgamma Pro12Ala polymorphism is associated with de-creased risk of type 2 diabetes. Nat Genet 2000. 26:76-80.
10. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G, Walker M, Levy JC, Sampson M, Halford S, et al. Large-scale association studies of vari-ants in genes encoding the pancreatic beta-cell KATP chan-nel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 dia-betes. Diabetes 2003. 52:568-572.
11. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001. 345:971-980.
12. Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, De MF, Durand E, Lepretre F, Lecoeur C, et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000. 67:1470-1480.
13. Wiltshire S, Hattersley AT, Hitman GA, Walker M, Levy JC, Sampson M, O'Rahilly S, Frayling TM, Bell JI, Lathrop GM, et al. A genomewide scan for loci pre-disposing to type 2 diabetes in a U.K. population (the Dia-betes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet 2001. 69:553-569.
14. Meigs JB, Panhuysen CI, Myers RH, Wilson PW, Cupples LA. A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. Diabetes 2002. 51:833-840.
15. Hsueh WC, St Jean PL, Mitchell BD, Pollin TI, Knowler WC, Ehm MG, Bell CJ, Sakul H, Wagner MJ, Burns DK, et al. Genome-wide and fine-mapping linkage studies of type 2 diabetes and glucose traits in the Old Order Amish: evidence for a new diabetes locus on chromosome 14q11 and confirmation of a locus on chromo-some 1q21-q24. Diabetes 2003. 52(2):550-557.
16. Xiang K, Wang Y, Zheng T, Jia W, Li J, Chen L, Shen K, Wu S, Lin X, Zhang G, et al. Genome-wide search for type 2 diabetes/impaired glucose homeostasis sus-ceptibility genes in the Chinese: significant linkage to chro-mosome 6q21-q23 and chromosome 1q21-q24. Diabetes 2004. 53:228-234.
17. Ng MC, So WY, Lam VK, Cockram CS, Bell GI, Cox NJ, Chan JC. Genome-wide scan for metabolic syn-drome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes 2004. 53:2676-2683.
18. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006. 38:320-323.
19. Jin T, Liu L. The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol Endocrinol 2008. 22:2383-2392.
20. Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep 2010. 10:306-315.
21. Morgan NG. Fatty acids and beta-cell toxicity. Curr Opin Clin Nutr Metab Care 2009. 12:117-122.
22. Lazar MA. How obesity causes diabetes: not a tall tale. Sci-ence 2005. 307:373-375.
23. Imamura M, Maeda S. Genetics of type 2 diabetes: the GWAS era and future perspectives. Endocr J 2011. 58:723-739.
24. Schafer SA, Machicao F, Fritsche A, Haring HU, Kantartzis K. New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Res Clin Pract 2011. 93(Suppl 1):S9-S24.
25. Mussig K, Staiger H, Machicao F, Haring HU, Fritsche A. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 2010. 53:2289-2297.
26. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resis-tance, diabetes mellitus and hypertension. Nature 1999. 402:880-883.
27. Radha V, Vimaleswaran KS, Babu HN, Abate N, Chandalia M, Satija P, Grundy SM, Ghosh S, Ma-jumder PP, Deepa R, et al. Role of genetic polymor-phism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneity. Diabetes Care 2006. 29:1046-1051.
28. Hani EH, Suaud L, Boutin P, Chevre JC, Durand E, Philippi A, Demenais F, Vionnet N, Furuta H, Velho G, et al. A missense mutation in hepatocyte nuclear factor-4 alpha, resulting in a reduced transactivation activity, in human late-onset non-insulin-dependent diabetes mellitus. J Clin Invest 1998. 101:521-526.
29. Macfarlane WM, Frayling TM, Ellard S, Evans JC, Allen LI, Bulman MP, Ayres S, Shepherd M, Clark P, Millward A, et al. Missense mutations in the insulin pro-moter factor-1 gene predispose to type 2 diabetes. J Clin In-vest 1999. 104:R33-R39.
30. Hani EH, Stoffers DA, Chevre JC, Durand E, Stanojevic V, Dina C, Habener JF, Froguel P. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 1999. 104:R41-R48.
31. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, et al. New genetic loci im-plicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010. 42:105-116.
32. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, et al. A common variant in the FTO gene is associated with body mass index and predis-poses to childhood and adult obesity. Science 2007. 316:889-894.
33. Lewis JP, Palmer ND, Ellington JB, Divers J, Ng MC, Lu L, Langefeld CD, Freedman BI, Bowden DW. Analysis of candidate genes on chromosome 20q12-13.1 reveals evidence for BMI mediated association of PREX1 with type 2 diabetes in European Americans. Ge-nomics 2010. 96:211-219.
34. Andersson EA, Holst B, Sparso T, Grarup N, Banasik K, Holmkvist J, Jorgensen T, Borch-Johnsen K, Egerod KL, Lauritzen T, et al. MTNR1B G24E variant associates With BMI and fasting plasma glucose in the gen-eral population in studies of 22,142 Europeans. Diabetes 2010. 59:1539-1548.
35. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, Delplanque J, Lobbens S, Rocheleau G, Durand E, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009. 41:89-94.
36. Ramracheya RD, Muller DS, Squires PE, Brereton H, Sugden D, Huang GC, Amiel SA, Jones PM, Per-saud SJ. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res 2008. 44:273-279.
37. Staiger H, Machicao F, Schafer SA, Kirchhoff K, Kantartzis K, Guthoff M, Silbernagel G, Stefan N, Haring HU, Fritsche A. Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS One 2008. 3:e3962.
38. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS. Peroxisome proliferator-activated receptor gene expression in human tis-sues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997. 99:2416-2422.
39. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Myk-kanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and im-proved insulin sensitivity. Nat Genet 1998. 20:284-287.
40. Wheeler E, Barroso I. Genome-wide association studies and type 2 diabetes. Brief Funct Genomics 2011. 10:52-60.
41. Cho YS, Chen CH, Hu C, Long J, Ong RT, Sim X, Takeuchi F, Wu Y, Go MJ, Yamauchi T, et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet 2012. 44:67-72.
42. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007. 167:1068-1074.
43. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nils-son P, Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008. 359:2220-2232.
44. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, Manning AK, Florez JC, Wilson PW, D'Agostino RB Sr, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008. 359:2208-2219.
45. de Miguel-Yanes JM, Shrader P, Pencina MJ, Fox CS, Manning AK, Grant RW, Dupuis J, Florez JC, D'Agostino RB Sr, Cupples LA, et al. Genetic risk re-classification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide poly-morphisms. Diabetes Care 2011. 34:121-125.
46. Janssens AC, Aulchenko YS, Elefante S, Borsboom GJ, Steyerberg EW, van Duijn CM. Predictive testing for complex diseases using multiple genes: fact or fiction? Genet Med 2006. 8:395-400.
47. Eichler EE, Flint J, Gibson G, Kong A, Leal SM, Moore JH, Nadeau JH. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet 2010. 11:446-450.
48. Jeon JP, Shim SM, Nam HY, Ryu GM, Hong EJ, Kim HL, Han BG. Copy number variation at leptin re-ceptor gene locus associated with metabolic traits and the risk of type 2 diabetes mellitus. BMC Genomics 2010. 11:426.
49. Craddock N, Hurles ME, Cardin N, Pearson RD, Plagnol V, Robson S, Vukcevic D, Barnes C, Conrad DF, Giannoulatou E, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 2010. 464:713-720.
50. Bell JT, Timpson NJ, Rayner NW, Zeggini E, Fray-ling TM, Hattersley AT, Morris AP, McCarthy MI. Genome-wide association scan allowing for epistasis in type 2 diabetes. Ann Hum Genet 2011. 75:10-19.
51. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001. 344:1343-1350.
52. Knowler WC, Barrett-Connor E, Fowler SE, Ham-man RF, Lachin JM, Walker EA, Nathan DM. Reduc-tion in the incidence of type 2 diabetes with lifestyle inter-vention or metformin. N Engl J Med 2002. 346:393-403.
53. Foster GD, Linder B, Baranowski T, Cooper DM, Goldberg L, Harrell JS, Kaufman F, Marcus MD, Trevino RP, Hirst K. A school-based intervention for diabetes risk reduction. N Engl J Med 2010. 363:443-453.
54. Lee DH, Lee IK, Song K, Steffes M, Toscano W, Baker BA, Jacobs DR Jr. A strong dose-response relation between serum concentrations of persistent organic pollut-ants and diabetes: results from the National Health and Ex-amination Survey 1999-2002. Diabetes Care 2006. 29:1638-1644.
55. Lee DH, Lee IK, Jin SH, Steffes M, Jacobs DR Jr. Association between serum concentrations of persistent or-ganic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Ex-amination Survey 1999-2002. Diabetes Care 2007. 30:622-628.
56. Porta M. Persistent organic pollutants and the burden of diabetes. Lancet 2006. 368:558-559.
57. Lee DH, Jacobs DR Jr, Porta M. Could low-level back- ground exposure to persistent organic pollutants contribute to the social burden of type 2 diabetes? J Epidemiol Commu-nity Health 2006. 60:1006-1008.
58. Lim S, Ahn SY, Song IC, Chung MH, Jang HC, Park KS, Lee KU, Pak YK, Lee HK. Chronic exposure to the herbicide, atrazine, causes mitochondrial dysfunction and in-sulin resistance. PLoS One 2009. 4:e5186.
59. Olsen H, Enan E, Matsumura F. Regulation of glucose transport in the NIH 3T3 L1 preadipocyte cell line by TCDD. Environ Health Perspect 1994. 102:454-458.
60. Brook RD, Jerrett M, Brook JR, Bard RL, Finkelstein MM. The relationship between diabetes mellitus and traffic-related air pollution. J Occup Environ Med 2008. 50:32-38.
61. Pearson JF, Bachireddy C, Shyamprasad S, Goldfine AB, Brownstein JS. Association between fine particulate matter and diabetes prevalence in the U.S. Diabetes Care 2010. 33:2196-2201.
62. Kramer U, Herder C, Sugiri D, Strassburger K, Schikowski T, Ranft U, Rathmann W. Traffic-related air pollution and incident type 2 diabetes: results from the SALIA cohort study. Environ Health Perspect 2010. 118:1273-1279.
63. Coogan PF, White LF, Jerrett M, Brook RD, Su JG, Seto E, Burnett R, Palmer JR, Rosenberg L. Air pol-lution and incidence of hypertension and diabetes mellitus in black women living in los angeles. Circulation 2012. 125:767-772.
64. Sun Q, Yue P, Deiuliis JA, Lumeng CN, Kampfrath T, Mikolaj MB, Cai Y, Ostrowski MC, Lu B, Par-thasarathy S, et al. Ambient air pollution exaggerates adi-pose inflammation and insulin resistance in a mouse model of diet-induced obesity. Circulation 2009. 119:538-546.
65. Longnecker MP, Daniels JL. Environmental contami-nants as etiologic factors for diabetes. Environ Health Perspect 2001. 109(Suppl 6):871-876.
66. Ceriello A. Oxidative stress and glycemic regulation. Metabolism 2000. 49:27-29.
67. Coyne T, Ibiebele TI, Baade PD, Dobson A, McClintock C, Dunn S, Leonard D, Shaw J. Diabetes mellitus and serum carotenoids: findings of a population-based study in Queensland, Australia. Am J Clin Nutr 2005. 82:685-693.
68. Salonen JT, Nyyssonen K, Tuomainen TP, Maenpaa PH, Korpela H, Kaplan GA, Lynch J, Helmrich SP, Salonen R. Increased risk of non-insulin dependent diabe-tes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. BMJ 1995. 311:1124-1127.
69. Sargeant LA, Wareham NJ, Bingham S, Day NE, Luben RN, Oakes S, Welch A, Khaw KT. Vitamin C and hyperglycemia in the European Prospective Investiga-tion into Cancer-Norfolk (EPIC-Norfolk) study: a popula-tion-based study. Diabetes Care 2000. 23:726-732.
70. Facchini F, Coulston AM, Reaven GM. Relation be-tween dietary vitamin intake and resistance to insulin-mediated glucose disposal in healthy volunteers. Am J Clin Nutr 1996. 63:946-949.
71. Feskens EJ, Virtanen SM, Rasanen L, Tuomilehto J, Stengard J, Pekkanen J, Nissinen A, Kromhout D. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995. 18:1104-1112.
72. Patel CJ, Bhattacharya J, Butte AJ. An Environment-Wide Association Study (EWAS) on type 2 diabetes mellitus. PLoS One 2010. 5:e10746.
73. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006. 355(3):241-250.
74. Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S, Meigs JB, et al. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with dia-betes incidence and regression to normoglycemia in the dia-betes prevention program. Diabetes 2011. 60:1340-1348.
75. Franks PW. Gene x environment interactions in type 2 diabetes. Curr Diab Rep 2011. 11:552-561.
76. Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, et al. Common variants near ATM are associated with glycemic response to met-formin in type 2 diabetes. Nat Genet 2011. 43:117-120.
77. Wagenknecht LE, Bowden DW, Carr JJ, Langefeld CD, Freedman BI, Rich SS. Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes 2001. 50(4):861-866.
78. Scheuner MT, Setodji CM, Pankow JS, Blumenthal RS, Keeler E. General Cardiovascular Risk Profile identifies advanced coronary artery calcium and is improved by family history: the multiethnic study of atherosclerosis. Circ Cardiovasc Genet 2010. 3:97-105.
79. Bild DE, Detrano R, Peterson D, Guerci A, Liu K, Shahar E, Ouyang P, Jackson S, Saad MF. Ethnic dif-ferences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005. 111(10):1313-1320.
80. Allison MA, Budoff MJ, Nasir K, Wong ND, Detrano R, Kronmal R, Takasu J, Criqui MH. Ethnic-specific risks for atherosclerotic calcification of the thoracic and ab-dominal aorta (from the Multi-Ethnic Study of Atheroscle-rosis). Am J Cardiol 2009. 104:812-817.
81. Lange LA, Bowden DW, Langefeld CD, Wagenknecht LE, Carr JJ, Rich SS, Riley WA, Freedman BI. Heritability of carotid artery intima-medial thickness in type 2 diabetes. Stroke 2002. 33(7):1876-1881.
82. Helgadottir A, Thorleifsson G, Manolescu A, Gre-tarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007. 316:1491-1493.
83. Doria A, Wojcik J, Xu R, Gervino EV, Hauser TH, Johnstone MT, Nolan D, Hu FB, Warram JH. Interac-tion between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. JAMA 2008. 300:2389-2397.
84. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common dis-eases and 3,000 shared controls. Nature 2007. 447:661-678.
85. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995. 44(4):369-374.
86. Cheng X, Shi L, Nie S, Wang F, Li X, Xu C, Wang P, Yang B, Li Q, Pan Z, et al. The same chromosome 9p21.3 locus is associated with type 2 diabetes and coronary artery disease in a Chinese Han population. Diabetes 2011. 60:680-684.
87. Bacci S, Menzaghi C, Ercolino T, Ma X, Rauseo A, Salvemini L, Vigna C, Fanelli R, Di MU, Doria A, et al. The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. Diabetes Care 2004. 27:2015-2020.
88. Qi L, Doria A, Manson JE, Meigs JB, Hunter D, Mantzoros CS, Hu FB. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes 2006. 55:1512-1516.
89. Lacquemant C, Froguel P, Lobbens S, Izzo P, Dina C, Ruiz J. The adiponectin gene SNP+45 is associated with coronary artery disease in Type 2 (non-insulin-dependent) diabetes mellitus. Diabet Med 2004. 21:776-781.
90. Filippi E, Sentinelli F, Romeo S, Arca M, Berni A, Tiberti C, Verrienti A, Fanelli M, Fallarino M, Sor-ropago G, et al. The adiponectin gene SNP+276G>T as-sociates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery dis-ease patients (age
91. Han LY, Wu QH, Jiao ML, Hao YH, Liang LB, Gao LJ, Legge DG, Quan H, Zhao MM, Ning N, et al. Associations between single-nucleotide polymorphisms (+45T>G, +276G>T,-11377C>G,-11391G>A) of adi-ponectin gene and type 2 diabetes mellitus: a systematic re-view and meta-analysis. Diabetologia 2011. 54:2303-2314.
92. Rask-Madsen C, King GL. Proatherosclerotic mecha-nisms involving protein kinase C in diabetes and insulin re-sistance. Arterioscler Thromb Vasc Biol 2005. 25:487-496.
93. Heyninck K, Beyaert R. A20 inhibits NF-kappaB activa-tion by dual ubiquitin-editing functions. Trends Biochem Sci 2005. 30:1-4.
94. Boonyasrisawat W, Eberle D, Bacci S, Zhang YY, Nolan D, Gervino EV, Johnstone MT, Trischitta V, Shoelson SE, Doria A. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabe-tes. Diabetes 2007. 56:499-505.
95. Maeda S. Genetics of diabetic nephropathy. Ther Adv Car- diovasc Dis 2008. 2:363-371.
96. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol 2007. 2:1306-1316.
97. Crook ED, Patel SR. Diabetic nephropathy in African- American patients. Curr Diab Rep 2004. 4:455-461.
98. Crook ED, Wofford P, Oliver B. Advanced diabetic nephropathy disproportionately affects African-American females: cross-sectional analysis and determinants of renal survival in an academic renal clinic. Ethn Dis 2003. 13:28-33.
99. Divers J, Freedman BI. Susceptibility genes in common complex kidney disease. Curr Opin Nephrol Hypertens 2010. 19:79-84.
100. Ma RC, Tam CH, Wang Y, Luk AO, Hu C, Yang X, Lam V, Chan AW, Ho JS, Chow CC, et al. Genetic variants of the protein kinase C-beta 1 gene and develop-ment of end-stage renal disease in patients with type 2 diabe-tes. JAMA 2010. 304:881-889.
101. Maeda S, Kobayashi MA, Araki S, Babazono T, Freedman BI, Bostrom MA, Cooke JN, Toyoda M, Umezono T, Tarnow L, et al. A single nucleotide poly-morphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet 2010. 6:e1000842.
102. Freedman BI, Langefeld CD, Lu L, Divers J, Comeau ME, Kopp JB, Winkler CA, Nelson GW, Johnson RC, Palmer ND, et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in African Americans. PLoS Genet 2011. 7:e1002150.
103. Tang SC, Leung VT, Chan LY, Wong SS, Chu DW, Leung JC, Ho YW, Lai KN, Ma L, Elbein SC, et al. The acetyl-coenzyme A carboxylase beta (ACACB) gene is associated with nephropathy in Chinese patients with type 2 diabetes. Nephrol Dial Transplant 2010. 25(12):3931-934.
104. Murea M, Freedman BI, Parks JS, Antinozzi PA, El-bein SC, Ma L. Lipotoxicity in diabetic nephropathy: the potential role of Fatty Acid oxidation. Clin J Am Soc Nephrol 2010. 5:2373-2379.
105. Lee SJ, Kim JY, Nogueiras R, Linares JF, Perez-Tilve D, Jung DY, Ko HJ, Hofmann SM, Drew A, Leitges M, et al. PKCzeta-regulated inflammation in the nonhema-topoietic compartment is critical for obesity-induced glucose intolerance. Cell Metab 2010. 12:65-77.
106. Liu L, Zheng T, Wang F, Wang N, Song Y, Li M, Li L, Jiang J, Zhao W. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 2010. 33:144-149.
107. Caramori ML, Canani LH, Costa LA, Gross JL. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003. 52:3010-3013.
108. Rema M, Saravanan G, Deepa R, Mohan V. Familial clustering of diabetic retinopathy in South Indian type 2 dia-betic patients. Diabet Med 2002. 19:910-916.
109. Hallman DM, Huber JC Jr, Gonzalez VH, Klein BE, Klein R, Hanis CL. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care 2005. 28:1163-1168.
110. Arar NH, Freedman BI, Adler SG, Iyengar SK, Chew EY, Davis MD, Satko SG, Bowden DW, Duggirala R, Elston RC, et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci 2008. 49:3839-3845.
111. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care 2003. 26:226-229.
112. Rani PK, Raman R, Gupta A, Pal SS, Kulothungan V, Sharma T. Albuminuria and Diabetic Retinopathy in Type 2 Diabetes Mellitus Sankara Nethralaya Diabetic Reti-nopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 12). Diabetol Metab Syndr 2011. 3:9.
113. Wu JC, Li XH, Peng YD, Wang JB, Tang JF, Wang YF. Association of two glyoxalase I gene polymorphisms with nephropathy and retinopathy in Type 2 diabetes. J En-docrinol Invest 2011. 34:e343-e348.
114. Wang Y, Ng MC, Lee SC, So WY, Tong PC, Cockram CS, Critchley JA, Chan JC. Phenotypic heterogene-ity and associations of two aldose reductase gene polymor-phisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 2003. 26:2410-2415.
115. Tian C, Fang S, Du X, Jia C. Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia 2011. 54:803-811.
116. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006. 114:597-605.
117. Niu W, Qi Y, Wu Z, Liu Y, Zhu D, Jin W. A meta-analysis of receptor for advanced glycation end products gene: Four well-evaluated polymorphisms with diabetes mellitus. Mol Cell Endocrinol 2012. 358(1):9-17.
118. Yuan D, Yuan D, Liu Q. Association of the receptor for advanced glycation end products gene polymorphisms with diabetic retinopathy in type 2 diabetes: a meta-analysis. Oph-thalmologica 2012. In press.
119. Niedowicz DM, Daleke DL. The role of oxidative stress in diabetic complications. Cell Biochem Biophys 2005. 43:289-330.
120. Cilensek I, Mankoc S, Petrovic MG, Petrovic D. GSTT1 null genotype is a risk factor for diabetic retinopathy in Caucasians with type 2 diabetes, whereas GSTM1 null genotype might confer protection against retinopathy. Dis Markers 2012. 32:93-99.
121. Toda N, Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Prog Retin Eye Res 2007. 26:205-238.
122. Cilensek I, Mankoc S, Petrovic MG, Petrovic D. The 4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (eNOS) gene predicts risk for prolifera- tive diabetic retinopathy in Slovenian patients (Caucasians) with type 2 diabetes mellitus. Mol Biol Rep 2012. In press.
123. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S. A common poly-morphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002. 51:1635-1639.
124. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic reti-nopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008. 18:263-269.
125. Gonzalez VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol 2009. 93:1474-1478.
126. Hsieh CH, Pei D, Hung YJ, Hsiao FC. Association be-tween retinoid-X receptor-gamma genetic polymorphisms and diabetic retinopathy. Genet Mol Res 2011. 10(4):3545-3551.
127. Yang B, Millward A, Demaine A. Functional differences between the susceptibility Z-2/C-106 and protective Z+2/T-106 promoter region polymorphisms of the aldose reductase gene may account for the association with diabetic microvascular complications. Biochim Biophys Acta 2003. 1639:1-7.
128. Ng DP. Human genetics of diabetic retinopathy: current perspectives. J Ophthalmol 2010. 2010.
129. Sobrin L, Green T, Sim X, Jensen RA, Tai ES, Tay WT, Wang JJ, Mitchell P, Sandholm N, Liu Y, et al. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci 2011. 52:7593-7602.
130. Sheetz MJ, King GL. Molecular understanding of hyper- glycemia's adverse effects for diabetic complications. JAMA 2002. 288:2579-2588.
131. Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 2010. 6:665-675.
132. Zaidi SK, Young DW, Montecino M, Lian JB, Stein JL, van Wijnen AJ, Stein GS. Architectural epigenetics: mitotic retention of mammalian transcriptional regulatory information. Mol Cell Biol 2010. 30:4758-4766.
133. Stein GS, Zaidi SK, Stein JL, Lian JB, van Wijnen AJ, Montecino M, Young DW, Javed A, Pratap J, Choi JY, et al. Transcription-factor-mediated epigenetic control of cell fate and lineage commitment. Biochem Cell Biol 2009. 87:1-6.
134. Chen S, Feng B, George B, Chakrabarti R, Chen M, Chakrabarti S. Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells. Am J Physiol Endocrinol Metab 2010. 298:E127-E137.
135. Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, Calkin AC, Brownlee M, Coo-per ME, El-Osta A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009. 58:1229-1236.
136. Intensive blood-glucose control with sulphonylureas or insuln copared with conventional treatment and risk of com-plications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998. 352(9131):837-853.
137. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008. 358:2560-2572.
138. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010. 363:233-244.
139. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010. 376:419-430.
140. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009. 360:129-139.
141. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008. 358:2545-2559.
142. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, et al. Long-term effects of in-tensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011. 364:818-828.